Indication: For the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Pharmacology: Brimonidine significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. It lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.
Mechanism Of Action: Brimonidine is an alpha adrenergic receptor agonist. It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
Drug Category: Antihypertensive Agents; EENT Drugs; ATC:S01EA05
Brand Names/Synonyms: Alphagan; Alphagan P; Brimonidine; Brimonidine Tartrate; Bromoxidine; CHEMBANK1623
Dosage Forms: 0.2% solution
Absorption: Minimal systemic absorption occurs after ocular insertion.
Interactions:
DrugBank: Interactions for Brimonidine
Interactions for Brimonidine:
Although specific drug interaction studies have not been conducted with ALPHAGAN®
P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates,
sedatives, or anesthetics) should be considered. Alpha-agonists, as a class, may reduce pulse and blood pressure.
Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac
glycosides is advised.
Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It
is not known whether the concurrent use of these agents with ALPHAGAN® P in humans can lead to
resulting interference with the IOP lowering effect. No data on the level of circulating catecholamines after
ALPHAGAN® P administration are available. Caution, however, is advised in patients taking
tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.
Chemical IUPAC Name: 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
Chemical Formula: C11H10BrN5
Half Life: 2 hours
Drug Type: Approved Drug
# Accession No: APRD00034
CAS Registry Number: 59803-98-4
